BRIEF-Moleculin Accelerates Planned Unblinded Data Readout For Miracle Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial To H2 2025

Reuters
14 Nov 2024

Nov 14 (Reuters) - Moleculin Biotech Inc :

* MOLECULIN ACCELERATES PLANNED UNBLINDED DATA READOUT FOR MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA $(AML.UK)$ PIVOTAL TRIAL TO H2 2025

* MOLECULIN ACCELERATES PLANNED UNBLINDED DATA READOUT FOR MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA $(AML.AU)$ PIVOTAL TRIAL TO H2 2025

* MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE TRIAL EXPECTED Q1 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10